Heart failure associated with sunitinib: Lessons learned from animal models

Current Hypertension Reports

Volumn 13, Issue 6, 2011, Pages 436-441

  Greineder, Colin F ^a   Kohnstamm, Sarah ^b   Ky, Bonnie ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMPK; Animal models; Cardiac dysfunction; Cardiotoxicity; Heart failure; Molecular mechanisms; PDGFRs; Sunitinib; VEGFRs

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOVIRUS VECTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG MEGADOSE; DRUG WITHDRAWAL; ENERGY TRANSFER; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MOLECULAR MECHANICS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; VIRAL GENE DELIVERY SYSTEM;

AMP-ACTIVATED PROTEIN KINASES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARDIOTOXINS; DISEASE MODELS, ANIMAL; GASTROINTESTINAL STROMAL TUMORS; HEART FAILURE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MITOCHONDRIA; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 81255136045     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0225-8     Document Type: Article

References (36)

1. TF Chu MA Rupnick R Kerkela, et al. 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 9604 2011 2019 18083403 10.1016/S0140-6736(07)61865-0 1:CAS:528:DC%2BD2sXhsVent7bN (Pubitemid 350236338)
2. Center for Drug Evaluation and Research: Pharmacology Review. NDA No. 21-938/21-968. SU011248/Sutent. Available at http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2006/021938-S000-Sutent-PharmR.pdf. Last accessed June 13, 2011.
3. Highlights of Prescribing Information: SUTENT® (sunitinib malate) capsules, oral. Available at http://labeling.pfizer.com/ShowLabeling.aspx?id= 607. Last accessed June 13, 2011.
4. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 5 332 344 17457301 10.1038/nrc2106 1:CAS:528:DC%2BD2sXksFSiu7w%3D (Pubitemid 46652481)
5. J Desai S Shankar MC Heinrich, et al. 2007 Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors Clin Cancer Res 13 18 Pt 1 5398 5405 17875769 10.1158/1078-0432.CCR-06-0858 1:CAS:528:DC%2BD2sXhtVCitLzP (Pubitemid 47510366)
6. H Cheng T Force 2010 Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics Circ Res 106 1 21 34 20056943 10.1161/CIRCRESAHA. 109.206920 1:CAS:528:DC%2BD1MXhs1aqt7nI This is a comprehensive review of the potential biologic mechanisms of current targeted cancer therapies
7. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
8. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. Publish Date: August 9, 2006. Available at: http://ctep.cancer.gov/protocoldevelopment/electronic- applications/docs/ctcaev3.pdf. Last accessed June 13, 2011.
9. ML Telli RM Witteles GA Fisher, et al. 2008 Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann Oncol 19 9 1613 1618 18436521 10.1093/annonc/mdn168 1:STN:280:DC%2BD1crivFWmsw%3D%3D
10. G Di Lorenzo R Autorino G Bruni, et al. 2009 Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann Oncol 20 9 1535 1542 19474115 10.1093/annonc/mdp025
11. AY Khakoo CM Kassiotis N Tannir, et al. 2008 Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor Cancer 112 11 2500 2508 18386829 10.1002/cncr.23460 1:CAS:528:DC%2BD1cXnsFGju78%3D
12. R Kerkela KC Woulfe JB Durand, et al. 2009 Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase Clin Transl Sci 2 1 15 25 20376335 10.1111/j.1752-8062.2008.00090.x 1:CAS:528:DC%2BD1MXntlemtrY%3D This is one of the few studies defining the effects of administering sunitinib to animals
13. Y Will JA Dykens S Nadanaciva, et al. 2008 Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells Toxicol Sci 106 1 153 161 18664550 10.1093/toxsci/kfn157 1:CAS:528:DC%2BD1cXht1emtb7I
14. BB Hasinoff D Patel KA O'Hara 2008 Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib Mol Pharmacol 74 6 1722 1728 18815214 10.1124/mol.108.050104 1:CAS:528: DC%2BD1cXhsVGls7rF
15. M Arad CE Seidman JG Seidman 2007 AMP-activated protein kinase in the heart: role during health and disease Circ Res 100 4 474 488 17332438 10.1161/01.RES.0000258446.23525.37 1:CAS:528:DC%2BD2sXitFylsb4%3D (Pubitemid 46673257)
16. HE Gruber ME Hoffer DR McAllister, et al. 1989 Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury Circulation 80 5 1400 1411 2553298 10.1161/01.CIR.80.5.1400 1:CAS:528:DyaK3cXjtVeqsQ%3D%3D (Pubitemid 19282530)
17. K Terai Y Hiramoto M Masaki, et al. 2005 AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress Mol Cell Biol 25 21 9554 9575 16227605 10.1128/MCB.25.21.9554-9575.2005 1:CAS:528:DC%2BD2MXhtFOns77O (Pubitemid 41507855)
18. P Zhang X Hu X Xu, et al. 2008 AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice Hypertension 52 5 918 924 18838626 10.1161/ HYPERTENSIONAHA.108.114702 1:CAS:528:DC%2BD1cXht1GgtbjO This is a key article defining the role of AMPK in the cardiovascular system
19. T Force R Kerkela 2008 Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem Drug Discov Today 13 17-18 778 784 18617014 10.1016/j.drudis.2008.05.011 1:CAS:528:DC%2BD1cXhtFaisb3O
20. JM Edelberg SH Lee M Kaur, et al. 2002 Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart Circulation 105 5 608 613 11827927 10.1161/hc0502.103672 1:CAS:528:DC%2BD38XhslGgsL8%3D (Pubitemid 34123436)
21. PC Hsieh C MacGillivray J Gannon, et al. 2006 Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity Circulation 114 7 637 644 16894033 10.1161/CIRCULATIONAHA.106.639831 1:CAS:528: DC%2BD28Xnsl2ht7o%3D (Pubitemid 44252305)
22. V Chintalgattu D Ai RR Langley, et al. 2010 Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress J Clin Invest 120 2 472 484 20071776 10.1172/JCI39434 1:CAS:528:DC%2BC3cXhsVOktL8%3D This is an outstanding study of the role of PDGFR-β in the maintenance of cardiac function
23. PC Hsieh ME Davis LK Lisowski, et al. 2006 Endothelial-cardiomyocyte interactions in cardiac development and repair Annu Rev Physiol 68 51 66 16460266 10.1146/annurev.physiol.68.040104.124629 1:CAS:528:DC%2BD28XksFWksr8%3D
24. H Helotera K Alitalo 2007 The VEGF family, the inside story Cell 130 4 591 592 17719536 10.1016/j.cell.2007.08.012 1:CAS:528:DC%2BD2sXhtVels77K (Pubitemid 47268069)
25. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 7070 932 936 16355210 10.1038/nature04478 1:CAS:528:DC%2BD2MXhtlSksrjF (Pubitemid 43093958)
26. D Abraham R Hofbauer R Schafer, et al. 2000 Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy Circ Res 87 8 644 647 11029398 1:CAS:528:DC%2BD3cXoslyjsLw%3D
27. Y Izumiya I Shiojima K Sato, et al. 2006 Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload Hypertension 47 5 887 893 16567591 10.1161/01.HYP.0000215207.54689.31 1:CAS:528:DC%2BD28XjsVeksrs%3D (Pubitemid 44297560)
28. M Pepe M Mamdani L Zentilin, et al. 2010 Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy Circ Res 106 12 1893 1903 20431055 10.1161/CIRCRESAHA.110.220855 1:CAS:528:DC%2BC3cXnvFWnt7s%3D This excellent study describes the effect of VEGF-B delivery on the nonischemic cardiomyopathy phenotype
29. Q Zhao M Ishibashi K Hiasa, et al. 2004 Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling Hypertension 44 3 264 270 15262905 10.1161/01.HYP.0000138688.78906.6b 1:CAS:528:DC%2BD2cXmslOmt7w%3D (Pubitemid 39172204)
30. T Tammela B Enholm K Alitalo, et al. 2005 The biology of vascular endothelial growth factors Cardiovasc Res 65 3 550 563 15664381 10.1016/j.cardiores.2004.12.002 1:CAS:528:DC%2BD2MXmsVKmtw%3D%3D (Pubitemid 40138976)
31. FM Belgore AD Blann FL Li-Saw-Hee, et al. 2001 Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension Am J Cardiol 87 6 805 807 11249912 10.1016/S0002-9149(00)01512-5 1:CAS:528:DC%2BD3MXhvVamsb4%3D A9 (Pubitemid 32209107)
32. K Walsh I Shiojima 2007 Cardiac growth and angiogenesis coordinated by intertissue interactions J Clin Invest 117 11 3176 3179 17975662 10.1172/JCI34126 1:CAS:528:DC%2BD2sXht12isr%2FM (Pubitemid 350096973)
33. SE Maynard JY Min J Merchan, et al. 2003 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 5 649 658 12618519 1:CAS:528:DC%2BD3sXhvFentbc%3D (Pubitemid 36278583)
34. RJ Levine SE Maynard C Qian, et al. 2004 Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 7 672 683 14764923 10.1056/NEJMoa031884 1:CAS:528:DC%2BD2cXhtFCrt7w%3D (Pubitemid 38364626)
35. FJ Giordano HP Gerber SP Williams, et al. 2001 A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function Proc Natl Acad Sci U S A 98 10 5780 5785 11331753 10.1073/pnas. 091415198 1:CAS:528:DC%2BD3MXjs1Wntr4%3D (Pubitemid 32435719)
36. L Zentilin U Puligadda V Lionetti, et al. 2010 Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction FASEB J 24 5 1467 1478 20019242 10.1096/fj.09-143180 1:CAS:528:DC%2BC3cXlslShsr0%3D